Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 46.60M P/E - EPS this Y 28.70% Ern Qtrly Grth -
Income -22.27M Forward P/E -2.52 EPS next Y 3.30% 50D Avg Chg -17.00%
Sales 55.18k PEG - EPS past 5Y - 200D Avg Chg -8.00%
Dividend N/A Price/Book 3.02 EPS next 5Y - 52W High Chg -39.00%
Recommedations 1.60 Quick Ratio 3.44 Shares Outstanding 16.22M 52W Low Chg 35.00%
Insider Own 16.45% ROA -65.14% Shares Float 14.26M Beta 0.43
Inst Own 11.90% ROE -141.57% Shares Shorted/Prior 149.60K/156.67K Price 3.78
Gross Margin - Profit Margin - Avg. Volume 48,300 Target Price 8.80
Oper. Margin -40,336.86% Earnings Date May 10 Volume 32,077 Change -5.03%
About Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Gain Therapeutics, Inc. News
04/24/24 Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
04/17/24 Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
04/10/24 Insiders are Piling into These 10 Healthcare Stocks in 2024
04/10/24 Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
04/09/24 Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
04/08/24 Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
04/01/24 Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)
04/01/24 Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
03/26/24 Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
03/15/24 Gain Therapeutics to Present at Public Ventures Discovery Day
03/05/24 EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease
03/05/24 Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
02/27/24 Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
02/14/24 Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
02/06/24 UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
02/06/24 Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
01/31/24 Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
01/24/24 Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know
01/02/24 Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
12/14/23 Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now
GANX Chatroom

User Image Holmun Posted - 24 minutes ago

$GANX Was MAD data expected to give the stock price a boost?

User Image Apiker Posted - 1 day ago

$GANX Gain Therapeutics (GANX) ARS2023 FY Annual report to shareholders (anybody interested this is available today.

User Image microcapspeculator Posted - 1 day ago

$GANX Buyers are sitting around $3. Letting seller come to them.

User Image FukSleepyJoe Posted - 1 day ago

$GANX where are all the pumpers? Oh yeah, they blocked me. Idiots

User Image FukSleepyJoe Posted - 2 days ago

$GANX piece of trash

User Image longhold845 Posted - 2 days ago

$GANX I think another substantial Capital add from green light would solidify confidence in buying at these levels.

User Image FukSleepyJoe Posted - 2 days ago

$GANX yup

User Image FukSleepyJoe Posted - 2 days ago

$GANX 2’s today?

User Image RealAvidTrader Posted - 2 days ago

$COYA $GANX $WULF

User Image Dodgeiiota40567 Posted - 2 days ago

$GANX whose that biddin it up after hours. that u mcclit?

User Image Dodgeiiota40567 Posted - 2 days ago

$GANX mcclit called bottom last time. it literally doubled from his last post here within a month. good omen!!!!

User Image RallyRaider Posted - 3 days ago

$GANX is buy on red

User Image FukSleepyJoe Posted - 3 days ago

$GANX could come out tomorrow and say they’ve cured Parkinson’s and it would still drop 7%.

User Image McClit Posted - 3 days ago

$GANX This is definitely not looking good. 2 ?!?!

User Image microcapspeculator Posted - 3 days ago

$GANX Gain touts positive Phase I results for Parkinson’s therapy - Clinical Trials Arena https://www.clinicaltrialsarena.com/news/gains-touts-positive-results-for-parkinsons-therapy-in-phase-i/

User Image monterocky848 Posted - 3 days ago

$GANX don’t worry biospecs usually have 2 or 3 bullshit pumps if they can beat dilution so u’ll probably have an out Joe sometime in the next couple years

User Image marvessa Posted - 3 days ago

$GANX frustrating days no doubt, even after good news yesterday, first pain , second money, be patient a bit

User Image FukSleepyJoe Posted - 3 days ago

$GANX starting to get very

User Image FukSleepyJoe Posted - 3 days ago

$GANX holy fuck

User Image DekmarTrades Posted - 3 days ago

THE HOTTEST Press Releases and Filings this Morning: $SMME $SITX $ULBI $GANX $CPSS $PCSA

User Image Jwa68 Posted - 3 days ago

$GANX Good listen. I agree with his comments on Small bios being attractive quick ways to rebuild major pharma pipelines. This and $COYA remain my two favorite small names. https://www.linkedin.com/posts/lou-basenese-174821128_fed-ai-gold-activity-7188873910388502530-q8KP?utm_source=share&utm_medium=member_android

User Image McClit Posted - 3 days ago

$GANX Damn...Wasn't this supposed to be at 5$ ? What happened here?

User Image FukSleepyJoe Posted - 3 days ago

$GANX ummmmmm.

User Image microcapspeculator Posted - 4 days ago

$GANX Here is all the data from posters. The market is so much bigger than Parkinsons if you start taking GT-02287 decades before the disease shows any affects and it never progresses. Gain Therapeutics(GANX): Preclinical data on Parkinsons, Alzheimers and Gaucher diseases continue to expand on the accumulating preclinical evidence supporting the potential disease-modifying properties of the novel small molecule candidates https://gaintherapeutics.wordpress.com/2023/04/15/gain-therapeuticsganx-preclinical-data-on-parkinsons-alzheimers-and-gaucher-diseases-continue-to-expand-on-the-accumulating-preclinical-evidence-supporting-the-potential-disease-modifying-properti/ Compelling preclinical data presented at WORLDSymposium™ earlier in February 2024 demonstrated that treatment with GT-02287 restored motor function and substantially reduced plasma levels of the emerging neurodegeneration biomarker NfL. Based on these data, GT-02287 may have the potential to slow the progression of Parkinson’s disease.

User Image FukSleepyJoe Posted - 4 days ago

$GANX worrisome to say the very least

User Image Dodgeiiota40567 Posted - 4 days ago

$GANX what does this tell us?

User Image marvessa Posted - 4 days ago

$GANX this makes no sense, 50 million market cap only , who is selling ?

User Image robingre Posted - 4 days ago

$GANX i’m good with it. —holding 6k shares. i’ll wait til PD patients to go all in.

User Image monterocky848 Posted - 4 days ago

$GANX well there’s the human news and nothing; so I guess this turns into the normal biospec; Dilution vs Progression battle commence;

User Image Aggieinvestor85 Posted - 4 days ago

$GANX

Analyst Ratings
HC Wainwright & Co. Buy Apr 25, 24
Oppenheimer Outperform Apr 23, 24
HC Wainwright & Co. Buy Apr 1, 24
Chardan Capital Buy Mar 27, 24
HC Wainwright & Co. Buy Dec 4, 23
HC Wainwright & Co. Buy Sep 18, 23
Maxim Group Buy Sep 12, 23
HC Wainwright & Co. Buy Aug 31, 23
Chardan Capital Buy Aug 14, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Calabrese Salvatore CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER May 19 Buy 8100 3,000 24,300,000 05/19/22
RICHMAN ERIC I Chief Executive Offi.. Chief Executive Officer Aug 16 Buy 7.866 4,922 38,716 216,820 04/21/22